[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-heart-disease-chd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-heart-disease-chd":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,50,82,110,129,152,173,195,227,252,275,296,322,344,366,393,416,441,461,489,517,539],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100644448","wearable-assessment-of-thoracic-cardiac-health-and-exercise-performance-trial-prospective-100644448",false,"NCT07663799","Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial Prospective","Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial Prospective (WATCH-XP)","WATCH-XP","Inclusion Criteria:\n\n* Age 20 to 70 years old\n* Ability to provide informed consent\n* History of the following cardiovascular conditions:\n* Adult congenital heart disease\n* Pulmonary hypertension\n* Heart failure\n* Coronary artery disease\n* Athletes undergoing cardiovascular assessment\n\nExclusion Criteria:\n\n* Contraindication for undergoing physical exertion including cardio-pulmonary exercise testing (CPX) and 6-minute walk test (6MWT)\n* Pregnancy\n* Known allergy to components of the investigational product","ALL","20 Years","70 Years",{"count":21,"type":22},20,"ESTIMATED","OBSERVATIONAL","Wearable health technology, particularly smartwatches, has revolutionized personal health monitoring by enabling continuous, non-invasive tracking of various physiological parameters. The potential applications of these devices in cardiology are extensive, but it is crucial to validate their accuracy against established medical-grade devices.\n\nThe Apple Watch Series 9 (Apple, USA) exemplifies the capabilities of modern smartwatches, offering a wide range of health tracking features. These include heart rate monitoring, detection of irregular heart rhythms suggestive of atrial fibrillation, electrocardiogram recording, blood oxygen level measurement, and comprehensive mobility metrics (including VO2 max, six-minute walk distance, walking speed, step length, double support time, and walking asymmetry). Many of these parameters are highly relevant for cardiovascular patients, potentially aiding in disease progression monitoring and adverse event prediction. However, there is a lack of comprehensive validation studies for these devices in specific cardiovascular disease populations.\n\nThis investigator-initiated, prospective observational study will consist of two phases: a training phase which involves 50 participants and a prospective validation phase which involves 20 participants. The study aims to validate smartwatch-based assessments using medical-grade devices and techniques. The study will focus on adult patients with congenital heart disease, pulmonary hypertension, heart failure, and coronary artery disease, as well as athletes undergoing cardiovascular assessment. By comparing smartwatch data with established clinical measurements, we seek to determine the reliability and potential clinical utility of these wearable devices in diverse cardiovascular contexts. Anonymized smartwatch data collected during the two phases will be published to a publicly registry to facilitate further research. This research will help bridge the gap between consumer-grade wearable technology and clinical practice in cardiology.",[26,27,28,29,30],"Congenital Heart Disease","Pulmonary Hypertension","Heart Failure","Coronary Heart Disease (CHD)","Apple Watch",[32,33,34,35,36],"apple watch","congenital heart disease","heart failure","coronary heart disease","pulmonary hypertension","NOT_YET_RECRUITING","2026-06-16",{"date":40,"type":41},"2026-06-23","ACTUAL",{"date":43,"type":22},"2026-08-01",{"date":45,"type":22},"2028-12-31",{"name":47,"class":48},"The University of Hong Kong","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100641047","single-vs-dual-antiplatelet-therapy-in-patients-undergoing-percutaneous-intervention-with-dcb-only-strategy-kong-freedom-i-100641047","NCT07587099","Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)","An Investigator-initiated, Multicenter, Open-label, Randomized Controlled Non-inferiority Trial to Assess the Single vs. Dual Antiplatelet Therapy in the Chronic Coronary Syndrome (CCS) and Stable Acute Coronary Syndrome (S-ACS) Patients Undergoing Percutaneous Intervention With Drug-coated Balloons (DCB)-Only Strategy (KONG-FREEDOM-I)","KONG-FREEDOM-I","Inclusion Criteria:\n\nSubjects who successfully underwent percutaneous coronary intervention (PCI) with drug-coated balloon (DCB) treatment without stent implantation are eligible for inclusion in this study if Male and female patients who meet the following criteria：\n\n1. Age ≥ 18 years.\n2. target lesion in vessels with diameter ≥2.0 and ≤4.5 mm (visual estimation).\n3. the total target vessels ≤2 and a total of target lesions ≤2.\n4. Total length of DCB used for target lesions \\\u003C60 mm.\n5. The subject's indication for PCI is chronic coronary syndrome (CCS) and stable Acute Coronary Syndrome (S-ACS), include Silent Ischemia, stable angina (SA), unstable angina (UA), non-ST-segment elevation myocardial (NSTEMI), or ST-segment elevation acute myocardial infarction (STEMI) with onset \\>2 weeks.\n6. All lesions were successfully treated with a drug-eluting balloon during routine clinical practice, i.e., post-procedural angiographic visual diameter stenosis \\\u003C30%.\n7. At the operator's discretion, no flow-limiting angiographic complications requiring extension of dual antiplatelet therapy (DAPT)have occurred.\n8. All PCI stages have been completed (if applicable), and no further PCI procedures are planned.\n\nInclusion criteria at the randomization visit within 24 hours post-index PCI:\n\nAt the time of the randomization visit (within 24 hours after successful drug-eluting balloon treatment during index PCI), the following criteria mustbe met:\n\nThe subject must have had an uneventful clinical course within 24 hours post-index PCI, i.e., no myocardial infarction,symptomatic restenosis, device-related thrombus formation, stroke, or any revascularization procedure (coronary or non-coronary)requiring extension of dual antiplatelet therapy.\n\nExclusion Criteria:\n\nPatients will be ineligible if they meet any of the following criteria:\n\n1. Stent implantation within 6 months prior to index percutaneous coronary intervention (PCI).\n2. Treatment for in-stent thrombosis (IST) at the time of index PCI or within 6 months prior to it.\n3. Treatment with a bioabsorbable stent at any time prior to index PCI.\n4. Acute myocardial infarction with ST-segment elevation within the past two weeks.\n5. True bifurcation lesions requiring treatment with two stents (Medina 1,1,1\u002F1,0,1\u002F0,1,1) with a branch vessel diameter≥2.5 mm (visual estimation).\n6. Chronic total occlusion of the target lesion (≥3 months).\n7. Unprotected left main coronary artery.\n8. Thrombus present in the target lesion (imaging\u002Fvisual).\n9. Total length of DCB used in the target lesion ≥60 mm.\n10. Active bleeding requiring medical intervention (BARC ≥2) at the time of randomization.\n11. Indications for long-term oral anticoagulation therapy.\n12. Life expectancy of less than 1 year.\n13. Known allergy or hypersensitivity to aspirin, clopidogrel, ticagrelor, or sirolimus.\n14. Currently participating in another trial and has not yet reached the primary endpoint.\n15. History of asthma induced by salicylates or substances with similar effects (particularly nonsteroidal anti-inflammatory drugs).\n16. Pregnant or breastfeeding women.\n17. Inability to understand and follow study-related instructions or to comply with the study protocol.\n18. Inability to provide written informed consent","18 Years",{"count":60,"type":22},2170,"INTERVENTIONAL",[63],"NA","This investigator-initiated, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) utilizing a P2Y12 inhibitor compared to dual antiplatelet therapy (DAPT) in the chronic coronary syndrome (CCS) and stable Acute Coronary Syndrome (S-ACS) patients undergoing percutaneous coronary intervention (PCI) with the latest generation rapamycin drug-coated balloon (DCB) without stent implantation. The study aims to assess rates of ischemic and bleeding adverse events.",[29],[67,68,69,70],"Coronary Heart Disease","Drug-Coated Balloon Angioplasty","P2Y12 Inhibitor Monotherapy","Non-Inferiority Clinical Trial","RECRUITING","2026-05-15",{"date":74,"type":41},"2026-05-19",{"date":76,"type":22},"2026-05-04",{"date":78,"type":22},"2030-12-31",{"name":80,"class":48},"Gan Lijun",3,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":61,"phases":92,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":49},"100611310","closed-loop-neurofeedback-targeting-the-right-dorsolateral-prefrontal-cortex-for-cardiac-autonomic-modulation-in-coronary-artery-disease-with-anxiety-100611310","NCT07238920","Closed-Loop Neurofeedback Targeting the Right Dorsolateral Prefrontal Cortex for Cardiac Autonomic Modulation in Coronary Artery Disease With Anxiety","Closed-Loop Neurofeedback Targeting the Right Dorsolateral Prefrontal Cortex for Cardiac Autonomic Modulation in Coronary Artery Disease With Anxiety - A Randomized, Sham-Controlled Trial","HEART-SET-1","Inclusion Criteria:\n\n* Age \\>18 years, any sex.\n* Right-handed, with resting heart rate between 60 and 100 beats per minute.\n* Confirmed diagnosis of CHD, defined as at least one of the following:\n\n  (i) positive stress test; (ii) documented myocardial infarction (MI) with electrocardiographic changes and concurrent elevation of creatine kinase MB isoenzyme or troponin; (iii) angiographically confirmed coronary atherosclerosis with ≥50% stenosis in at least one coronary artery.\n* Diagnosis of an anxiety disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).\n* Hamilton Anxiety Rating Scale (HAMA) score ≥16 and 17-item Hamilton Depression Rating Scale (HAMD-17) score ≤17.\n\nExclusion Criteria:\n\n* Acute unstable angina.\n* Severe congestive heart failure (New York Heart Association \\[NYHA\\] class IV).\n* Valvular heart disease.\n* History of atrial fibrillation.\n* Unstable blood pressure, defined as systolic blood pressure \\>180 mmHg or \\\u003C90 mmHg.\n* Pregnancy.\n* History of unstable medical conditions, including cerebrovascular disease, dementia, hyperthyroidism, pulmonary disease, or malignancy. These are assessed through medical history, electronic health records, physical examination, and ECG findings.\n* High risk of suicide or homicide.\n* Presence of other psychiatric disorders, including psychotic disorders, bipolar disorder, or active substance use disorders.\n* Use of psychotropic medication within 1 month prior to enrolment, to avoid potential interference with haemodynamic measurements.",{"count":91,"type":22},56,[63],"The goal of this clinical trial is to test whether real-time fNIRS-BCI neurofeedback targeting the right dorsolateral prefrontal cortex (right DLPFC), using active volitional control during a slow-wave auditory acoustic paradigm, can suppress cardiac sympathetic activity and improve autonomic regulation in right-handed patients with stable coronary heart disease (CHD) and comorbid DSM-5 anxiety.\n\nThe main questions it aims to answer are:\n\nDoes real neurofeedback, compared with sham, reduce baseline-corrected heart rate during the auditory stimulation window? Does real neurofeedback, compared with sham, increase HRV spectral power around 0.0167 Hz (1\u002F60 Hz) and produce stronger suppression of right DLPFC activation? Does suppression of right DLPFC activation mediate the effect of group assignment on heart rate?\n\nIf there is a comparison group: Researchers will compare the real neurofeedback group with the sham (non-contingent) feedback group, which uses identical audio and interface, to determine whether coupling feedback to right DLPFC activity yields autonomic benefits.\n\nParticipants will:\n\nComplete eligibility screening in cardiology and psychiatry and provide informed consent; baseline demographics, medical history, vital signs, and medications are recorded (HAMA\u002FHAMD used for eligibility only).\n\nUndergo a 3-day adaptation phase to practice active volitional self-regulation while viewing a real-time energy bar mapped to right DLPFC statistics; adaptation data are not analyzed for outcomes.\n\nAttend two formal sessions (Days 4-5), each with 15 blocks of 60 s (20 s rest + 40 s stimulus). The auditory stimulus is a 1 Hz amplitude-modulated pure tone at approximately 60 dB; 10-second white-noise bursts are randomly embedded within the 40-second window. During the stimulation period, participants receive real or sham feedback on right DLPFC activation and act to push the energy bar below an unlabeled threshold line using active volitional strategies.\n\nUndergo synchronous fNIRS (HbO) and 3-lead ECG (1,000 Hz) recording throughout; online processing and rendering performance metrics are logged; adverse events are monitored and managed per protocol.",[29,95],"Anxiety Disorders",[97,98,99,100],"Coronary heart disease","Anxiety","Neurofeedback","Heart rate variability","2026-04-21",{"date":103,"type":41},"2026-04-22",{"date":105,"type":41},"2025-11-19",{"date":107,"type":22},"2026-08-21",{"name":109,"class":48},"Shenyang Medical College",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":61,"phases":118,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":49},"100611738","closed-loop-neurofeedback-targeting-the-left-dorsolateral-prefrontal-cortex-for-cardiac-autonomic-modulation-in-coronary-artery-disease-with-anxiety-100611738","NCT07244484","Closed-Loop Neurofeedback Targeting the Left Dorsolateral Prefrontal Cortex for Cardiac Autonomic Modulation in Coronary Artery Disease With Anxiety","Closed-Loop Neurofeedback Targeting the Left Dorsolateral Prefrontal Cortex for Cardiac Autonomic Modulation in Coronary Artery Disease With Anxiety - A Randomized, Sham-Controlled Trial (HEART-SET-2)","HEART-SET-2",{"count":91,"type":22},[63],"The goal of this clinical trial is to test whether closed-loop fNIRS-BCI neurofeedback(NF) targeting the left dorsolateral prefrontal cortex(DLPFC) can reduce cardiac autonomic arousal, indexed by baseline-corrected heart rate(HR) under cold-induced pain stress, in adults with stable coronary heart disease(CHD) and comorbid anxiety.\n\nThe main questions it aims to answer are:\n\nDoes real left DLPFC neurofeedback, compared with sham neurofeedback, lead to a greater reduction in baseline-corrected HR during the cold-induced pain stimulation window?\n\nDoes real neurofeedback produce stronger volitional upregulation of left DLPFC activation and higher inter-hemispheric synchronisation between left and right DLPFC than sham neurofeedback?\n\nAre changes in baseline-corrected HR statistically associated with, and partly mediated by, changes in left DLPFC activation or DLPFC inter-hemispheric synchronisation?\n\nWhat adverse events(AEs) occur during adaptive training and the formal experimental session, and do AE rates differ between the two groups?\n\nResearchers will compare a real neurofeedback group with a sham neurofeedback group to determine whether targeting the left DLPFC via closed-loop fNIRS-BCI yields superior modulation of cardiac autonomic responses and prefrontal activation patterns in CHD patients with anxiety.\n\nParticipants will:\n\nundergo cardiac and psychiatric screening to confirm stable CHD, DSM-5 anxiety disorder, and other eligibility criteria;\n\nattend three adaptive training sessions(days 1-3) with fNIRS-BCI neurofeedback targeting the left DLPFC, combined with slow-wave auditory stimulation and mild cold-water exposure, while ECG is recorded;\n\non day 4, complete one formal experimental session consisting of 15 blocks of cold-induced pain stimulation and slow-wave auditory stimulation, with simultaneous fNIRS and ECG recording, receiving either real or sham left DLPFC neurofeedback according to randomisation, and continuous monitoring for adverse events.",[29,95],[97,98,99,122],"the dorsolateral prefrontal cortex",{"date":103,"type":41},{"date":125,"type":41},"2025-11-23",{"date":127,"type":22},"2026-05-30",{"name":109,"class":48},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":61,"phases":137,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100620464","the-effectiveness-of-a-theory-driven-behavioral-change-intervention-on-sedentary-behavior-in-individuals-with-coronary-heart-disease-a-randomised-controlled-trial-100620464","NCT07357961","The Effectiveness of a Theory-driven Behavioral Change Intervention on Sedentary Behavior in Individuals With Coronary Heart Disease: A Randomised Controlled Trial","Inclusion Criteria:\n\n1. Adult 18 years old and above\n2. Diagnosed with coronary heart disease within one year\n3. Engaged in MVPA less than 150 minutes per week and a minimum of 8 hours total sedentary time per day, both assessed using the Global Physical Activity Questionnaire\n4. Able to communicate in Cantonese\n5. Obtained medical clearance for physical activity (no medical contraindications to exercise, including walking)\n6. Being able to understand and give informed consent\n7. Having telephone access, text messaging services or WhatsApp\n\nExclusion Criteria:\n\n1. Cannot perform brisk walking exercise\n2. Unable to perform PA independently\n3. Cognitive impairments, as indicated by an abbreviated mental test score of less than 7\n4. Currently enrolled in another clinical trial focusing on limiting SB with\u002Fwithout enhancing PA\n5. Doctor-diagnosed psychiatric illness",{"count":136,"type":22},232,[63],"The objective of this randomised controlled trial is to examine the effectiveness of a theory-driven behavioural change intervention on total sedentary time (primary outcomes), moderate-to-vigorous physical activity time, intention of behavioural change, future time perception, behavioural prepotency, self-regulation capacity, and exercise capacity in individuals with coronary heart disease.\n\nHypotheses:\n\nCompared to the participants in the control group, participants in the intervention group will demonstrate:\n\n1. Significantly less total sedentary time\n2. Significantly improved MVPA time,\n3. Significantly better intention of behavioural change,\n4. Significantly higher level of behavioural prepotency,\n5. Significantly enhanced self-regulation capacity, and\n6. Significantly greater future time perception\n7. Significantly better exercise capacity at the immediate post-intervention (T1), the 1-month post-intervention (T2), and the 6-month post-intervention (T3).\n\nParticipants will:\n\nParticipants in the intervention group will participate in a theory-driven behavioural change intervention over three months, comprising four individual face-to-face sessions (45 minutes each) and four individual telephone sessions (20 minutes each), along with the usual care.\n\nParticipants in the attention control group will continue to have the usual care, which includes regular follow-up at the cardiac clinic. Education sessions, consisting of information about healthy lifestyles, except physical activity and sedentary behaviour, with the same schedule as the intervention group, will be provided to account for potential attention effects from contacts.",[29],[141,142],"sedentary behaviour","movement behaviours","2026-04-20",{"date":145,"type":41},"2026-04-23",{"date":147,"type":22},"2026-04-13",{"date":149,"type":22},"2026-10-31",{"name":151,"class":48},"Chinese University of Hong Kong",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":4},"100634032","the-prognostic-value-of-cardiopulmonary-exercise-testing-parameters-in-patients-with-coronary-heart-disease-a-retrospective-cohort-studycpetpcad-100634032","NCT07534410","The Prognostic Value of Cardiopulmonary Exercise Testing Parameters in Patients With Coronary Heart Disease: A Retrospective Cohort Study(CPETPCAD)","The Prognostic Value of Cardiopulmonary Exercise Testing Parameters in Patients With Coronary Heart Disease: A Retrospective Cohort Study","CPET-PCHD","Inclusion Criteria:\n\n1. Our hospital has diagnosed coronary heart disease and conducted cardiopulmonary exercise tests.\n2. Patients with complete clinical data.\n\nExclusion Criteria:\n\n1. Uncontrolled heart failure (NYHA classification Ⅲ-IV grade).\n2. Complications, such as moderate to severe anemia, tumors and lung diseases.\n3. Complicated with valvular heart disease.\n4. Unable to reach the anaerobic threshold during exercise.",{"count":161,"type":22},15000,"Parameters related to cardiopulmonary exercise testing (CPET) are important objective indicators for evaluating cardiopulmonary function in patients with coronary heart disease. However, the clinical application of CPET parameters in the prognostic assessment of patients with coronary heart disease remains unclear. This is a retrospective cohort study designed to systematically collect real-world clinical data and long-term follow-up outcomes of patients with coronary heart disease. Through standardized follow-up, this study will investigate the association between CPET parameters and adverse clinical outcomes in patients with coronary heart disease, as well as the relevant risk factors.",[29],"2026-04-09",{"date":166,"type":41},"2026-04-16",{"date":168,"type":22},"2026-04-07",{"date":170,"type":22},"2027-06-30",{"name":172,"class":48},"Xinjiang Medical University",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":17,"minAge":180,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":61,"phases":184,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":49},"100529189","core-compare-pilot-study-100529189","NCT06170541","CORE-COMPARE Pilot Study","Ultra-High Resolution Computed Tomography (CT) vs. Conventional CT for Detecting Obstructive Coronary Artery Disease (CAD) The CORE-COMPARE Pilot Study","Inclusion Criteria:\n\n* Patients aged 21-85 years\n* Clinical history suggestive of CHD who are referred by their primary cardiologist for further evaluation via Computed tomography angiography (CTA) will be asked to participate.\n* Women of child bearing potential must demonstrate a negative pregnancy test within 24 hours of the study CTA.\n* Ability to understand and willingness to sign the Informed Consent Form.\n\nExclusion Criteria:\n\n* Known allergy to iodinated contrast media.\n* History of multiple myeloma or previous organ transplantation\n* Elevated serum creatinine (\\> 1.5mg\u002Fdl) OR calculated creatinine clearance of \\\u003C 60 ml\u002Fmin (using the Cockcroft-Gault formula\n* Atrial fibrillation or uncontrolled tachyarrhythmia, or advanced atrioventricular block (second or third degree heart block)\n* Evidence of severe symptomatic heart failure (NYHA Class III or IV);\n* Known or suspected moderate or severe aortic stenosis\n* History of prior percutaneous coronary intervention (PCI) in one or more vessel or history of coronary arterial bypass grafting (CABG)\n* Suspected acute coronary syndrome\n* Presence of any other history or condition that the investigator feels would be problematic","21 Years","85 Years",{"count":183,"type":22},140,[63],"The utility of Ultra High-Resolution Computed Tomography (UHR-CT) compared to conventional CT in all-comers (i.e., a generally lower-risk population) remains uncertain but is an important area of study in order to justify wider spread implementation and use of this technology, particularly in light of reports of significantly higher radiation exposure with UHR-CT, as well as longer scan times. The availability of technology to reconstruct conventional resolution (CR) simulation images from the raw CT acquisition data acquired on the UHR-CT scanner offers a unique platform to study this question without subjecting individuals to two different scans.\n\nThe primary objective of this study is to generate preliminary data in support of the hypothesis that noninvasive UHR-CT is superior to conventional resolution CT for identifying patients with obstructive CHD.",[29],"2026-04-08",{"date":147,"type":41},{"date":190,"type":41},"2021-04-05",{"date":192,"type":22},"2027-12",{"name":194,"class":48},"Johns Hopkins University",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":181,"enrollmentInfo":203,"targetDuration":4,"studyType":61,"phases":205,"briefSummary":207,"conditions":208,"keywords":209,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":4},"100628491","phase-4-proteomic-and-inflammatory-omics-changes-with-colchicine-therapy-in-coronary-heart-disease-100628491","NCT07462325","Proteomic and Inflammatory Omics Changes With Colchicine Therapy in Coronary Heart Disease","Proteomic Changes Before and After Colchicine Treatment in hsCRP-Elevated Coronary Heart Disease Patients: A Randomized Controlled Open-Label Study","PIC-CHD","Inclusion Criteria:\n\n* Diagnosis \\& Treatment: Have symptoms or objective evidence of myocardial ischemia and have undergone successful Percutaneous Coronary Intervention (PCI).\n\nInflammation Status: Have a plasma high-sensitivity C-reactive protein (hs-CRP) level ≥ 2 mg\u002FL at the time of screening.\n\nBackground Therapy: Be on guideline-directed standard medical therapy for coronary heart disease, tailored to their individual clinical condition.\n\nInformed Consent: The participant or their legally authorized representative must be capable of understanding the study and must provide written informed consent.\n\nExclusion Criteria:\n\n* Recent Cardiac Event: Acute Myocardial Infarction within the past 1 month. Drug Intolerance: Known allergy or intolerance to colchicine.\n\nHematologic Abnormalities:\n\nPlatelet count \\\u003C 110 × 10⁹\u002FL White blood cell count \\\u003C 4.0 × 10⁹\u002FL Hemoglobin level \\\u003C 115 g\u002FL\n\nRenal Impairment:\n\nEstimated Glomerular Filtration Rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m² (calculated using the MDRD formula), OR Serum creatinine level \\> 2 times the upper limit of normal (ULN).\n\nHepatic Impairment:\n\nSevere liver cirrhosis, biliary cirrhosis, or cholestasis, OR Liver enzyme (transaminase) levels \\> 3 times the ULN. Bone Marrow Disorder: Known history of bone marrow hypoplasia.\n\nSevere Cardiac Conditions:\n\nNew York Heart Association (NYHA) Class III-IV heart failure, OR Left Ventricular Ejection Fraction (LVEF) \\\u003C 35%, OR Moderate or severe valvular heart disease requiring intervention. Recent Cerebrovascular Event\u002FInstability: Stroke within the past 3 months, or current cardiogenic shock or hemodynamic instability.\n\nActive Malignancy: Concurrent active tumor or cancer. Chronic Pulmonary Disease: Chronic Obstructive Pulmonary Disease (COPD) or other chronic lung diseases.\n\nInflammatory Bowel Disease (IBD) or Chronic Diarrhea: e.g., Crohn's disease, ulcerative colitis.\n\nUncontrolled Comorbidities: Any other uncontrolled disease or condition that, in the investigator's judgment, would place the participant at undue risk by participating in the study.\n\nActive Systemic Inflammation\u002FInfection: Presence of systemic inflammation or acute infection at the time of enrollment.\n\nConcurrent Steroid Use: Current use or planned initiation of systemic corticosteroid therapy during the study period (excluding topical or inhaled steroids).\n\nPregnancy\u002FBreastfeeding: Women who are pregnant, planning to become pregnant, or breastfeeding.\n\nConcurrent Trial Participation: Participation in another interventional clinical trial within the past 3 months that may interfere with the outcomes of this study.",{"count":204,"type":22},176,[206],"PHASE4","The goal of this exploratory clinical trial is to investigate the proteomic changes induced by low-dose colchicine anti-inflammatory therapy in coronary heart disease (CHD) patients, with the aim of identifying novel biomarkers and therapeutic targets.\n\nThe main questions it aims to answer are:\n\n* Whether short-term colchicine treatment induces significant changes in the plasma proteomic profile of post-PCI CHD patients with residual inflammation.\n* Which specific proteins or pathways are dynamically modulated by colchicine, indicating potential mechanisms of action and drug targets.\n* How the proteomic expression profiles differ between patients treated with colchicine and matched controls after one month.\n\nParticipants, recruited based on a prior RCT framework, will be post-PCI CHD patients with elevated inflammation (hs-CRP ≥ 2 mg\u002FL). A total of 176 participants will be enrolled: 88 in the trial group (colchicine 0.5 mg\u002Fday) and 88 in the matched control group (no intervention). All participants will complete a one-month follow-up. Peripheral blood samples will be collected at baseline and at the one-month visit for high-throughput proteomic analysis using Olink technology.",[29],[210,211,212,213,214,215,216,217],"Colchicine","Proteomics","Biomarkers","Olink","Anti-Inflammatory Therapy","Randomized Controlled Trial (RCT)","High-Throughput Screening","Precision Medicine","2026-03-17",{"date":220,"type":41},"2026-03-19",{"date":222,"type":22},"2026-03-01",{"date":224,"type":22},"2027-03-31",{"name":226,"class":48},"Chinese Academy of Medical Sciences, Fuwai Hospital",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":61,"phases":237,"briefSummary":238,"conditions":239,"keywords":240,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":4},"100624848","scalable-clinical-oversight-of-large-language-models-via-uncertainty-triangulation-100624848","NCT07414966","Scalable Clinical Oversight of Large Language Models Via Uncertainty Triangulation","Prospective Evaluation of a Model-Agnostic Meta-Verification Framework (SCOUT) for Scalable Clinical Oversight of Large Language Model Outputs in Coronary Heart Disease Diagnosis: A Multi-Reader, Randomized, Crossover Trial","SCOUT","Inclusion Criteria:\n\n* Board-certified or in-training cardiologists at Fuwai Hospital\n* Spanning three experience strata: junior residents, senior residents, attending physicians\n\nExclusion Criteria:\n\n* Clinicians involved in the development or optimization of the SCOUT framework\n* Clinicians involved in the gold-standard adjudication process",{"count":236,"type":22},7,[63],"This prospective, multi-reader, randomized crossover trial evaluates SCOUT (Scalable Clinical Oversight via Uncertainty Triangulation), a model-agnostic meta-verification framework that selectively defers unreliable large language model (LLM) predictions to clinicians by triangulating three orthogonal uncertainty signals: model heterogeneity, stochastic inconsistency, and reasoning critique. The trial assesses whether SCOUT-assisted review can reduce physician review time compared with standard manual review of AI-generated diagnoses while maintaining non-inferior diagnostic accuracy in coronary heart disease (CHD) subtyping.",[29],[241],"artificial intelligence","2026-02-14",{"date":244,"type":41},"2026-02-17",{"date":246,"type":22},"2026-02-19",{"date":248,"type":22},"2026-02-28",{"name":250,"class":251},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":261,"conditions":262,"keywords":264,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":49},"100565986","a-prospective-multicenter-clinical-study-intracoronary-near-infrared-spectroscopy-and-optical-coherence-tomography-for-evaluating-coronary-vulnerable-plaque-in-patients-with-diabetes-100565986","NCT06649305","A Prospective Multicenter Clinical Study： IntracOronary neaR-Infrared Spectroscopy and OptIcal Coherence Tomography for Evaluating Coronary vulNerable Plaque in Patients With diabeTes","A Prospective Multicenter Clinical Study：IntracOnary neaR-Infrared Spectroscopy and OptIcal Coherence Tomography for Evaluating Coronary vulNerable Plaque in Patients With diabeTes","Inclusion Criteria:\n\n1. 18 years old or older, gender is not limited\n2. Patients with diabetes who require an OCT examination or treatment under OCT guidance (diabetes definition: active treatment with insulin or oral hypoglycemic agents at admission). For patients with diabetes who are treated with diet only, abnormal fasting blood sugar (\\>7 mmol\u002Fl), blood sugar \\>11.1 mmol\u002Fl at any time, or abnormal glucose tolerance tests based on World Health Organization standards need to be recorded.\n3. Be able to understand the purpose of clinical research, voluntarily participate can complete the observation as required and sign the informed consent form\n\n5: Lesion stenosis greater than or equal to 50% without interventional treatment\n\n6: The diameter of the blood vessel in the diseased segment is greater than or equal to 2.5 mm\n\nExclusion Criteria:\n\n* 1: Severe coagulation dysfunction (APTT greater than 3 times the upper limit of the normal range)\n\n  2: Severe hemodynamic disorder or shock that cannot be corrected\n\n  3: Patients with renal impairment（eGFR\\\u003C30 mL\u002Fmin\u002F1.73m2）\n\n  4: Severe symptoms of heart failure (NYHA III and above) or left ventricular ejection fraction \\\u003C30%\n\n  5: The presence or suspected presence of infective endocarditis or systemic active infection\n\n  6: Patients with refractory ventricular arrhythmias who have previously undergone coronary bypass transplantation (CABG) or plan to undergo CABG during the study\n\n  7: Patients with serious concurrent diseases such as advanced cancer have a life expectancy of less than 24 months\n\n  8: Pregnant or lactating women, have a family plan within 24 months or are unwilling to take effective contraceptive measures\n\n  9: The target vessel has severe calcification or severe tortuosity, which cannot be examined by OCT\n\n  10: Have participated in other clinical trials or are participating in other drug\u002Fdevice clinical trials within 3 months prior to enrollment and have not met the primary endpoint\n\n  11: Investigators believe that those who are unnecessary for OCT or not suitable for inclusion in this trial.\n\n  12: There are multiple lesions in the same blood vessel, and the non-target lesion distance requiring treatment vascular segment is less than 5mm",{"count":260,"type":22},1516,"To evaluate the correlation between maxLCBI4mm\u002FFCTmin(a new index of lipid plaque based on NIRS-OCT technology) and fiber cap thickness , and the prognosis of patients, providing a new quantitative index for early, accurate and comprehensive identification of vulnerable plaques, and exploring preventive measures for adverse events such as cardiac death and recurrent myocardial infarction caused by vulnerable plaques, so as to improve the long-term prognosis of patients.",[29,263],"Diabetes (DM)",[265],"near-infrared spectroscopy","2026-02-09",{"date":268,"type":41},"2026-02-12",{"date":270,"type":41},"2024-10-30",{"date":272,"type":22},"2027-09-30",{"name":274,"class":48},"Shanghai Zhongshan Hospital",{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":283,"enrollmentInfo":284,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":49},"100588032","residual-risk-under-intensive-lipid-lowering-therapy-in-coronary-heart-disease-100588032","NCT06936111","REsiduAL rISk Under Intensive Lipid-lowering Therapy In Coronary Heart Disease","Effect of Residual Lipid and Inflammation Risk on Atherosclerotic Plaque Progression Under Intensive Lipid-lowering Therapy in Coronary Heart Disease","REALISTIC","Inclusion Criteria:\n\n* Diagnosed with CAD and PCI was successfully performed.\n* Presence of non-target lesions near the target lesion (more than 5mm proximal or distal), with stenosis of 20% to 50% and identifiable anatomical markers (e.g., branches, calcifications, stent edges).\n* 18 to 75 years old.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Known autoimmune diseases, or taking immunosuppressive drugs for a long time before onset.\n* Known familial hypercholesterolemia.\n* Critical conditions (e.g., cardiogenic shock, acute heart failure).\n* Severe renal insufficiency (eGFR \\\u003C 30 mL \u002F(min·1.73m2)), or severe hepatic insufficiency (ALT or AST≥3 times the upper limit of normal).\n* Severe underlying diseases (such as end-stage malignancies), life expectancy \\\u003C 1 year.\n* Allergic to lipid-lowering medications.\n* Pregnant, or trying to become pregnant, and breastfeeding women.\n* Other conditions deemed unsuitable for inclusion by the researcher.","75 Years",{"count":285,"type":22},900,"Intensive lipid-lowering therapy is a cornerstone treatment for coronary heart disease (CHD). However, coronary plaque progression persists in a subset of patients even under intensive lipid-lowering therapy, which may be associated with residual lipid and inflammatory risks. Current research in this area remains largely confined to post hoc analyses of randomized controlled trials , with a notable scarcity of prospective follow-up cohorts. The investigators propose that establishing a prospective cohort will provide more authentic insights into the associations between residual risk factors and plaque progression. In this project, the investigators aim to establish a well-characterized CHD cohort with comprehensive data collection, good compliance, and an appropriate sample size. By focusing on non-target lesions within the target vessel and utilizing intravascular ultrasound (IVUS), the investigators will investigate the impact of residual lipid and inflammatory risks on plaque progression during intensive lipid-lowering therapy.",[29],"2026-01-30",{"date":290,"type":41},"2026-02-03",{"date":292,"type":41},"2025-07-01",{"date":294,"type":22},"2027-07",{"name":274,"class":48},{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":304,"targetDuration":306,"studyType":23,"phases":4,"briefSummary":307,"conditions":308,"keywords":309,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":49},"100616953","ai-driven-dynamic-prediction-of-non-target-lesion-progression-after-pci-a-chinese-multicenter-cohort-study-100616953","NCT07312318","AI-Driven Dynamic Prediction of Non-Target Lesion Progression After PCI: A Chinese Multicenter Cohort Study","DeVelopment of an Artificial Intelligence-Driven Dynamic Prediction and Precision Stratification System for Coronary Non-Target LesIon ProgressiON After Percutaneous Coronary Intervention: A Multimodal Data-Enabled Multicenter Cohort Study in China","VISION-PCI","Inclusion Criteria:\n\n1. Aged 18 years or older;\n2. Scheduled for or having undergone PCI;\n3. Baseline plasma sample obtainable;\n4. Informed consent obtained\n\nExclusion Criteria:\n\n1. Pregnancy or lactation;\n2. Severe hepatic or renal dysfunction;\n3. Active autoimmune disease;\n4. Missing critical data",{"count":305,"type":22},12000,"12 Years","Coronary artery disease remains a leading cause of global mortality. Although percutaneous coronary intervention (PCI) improves patient outcomes, the long-term risk of major adverse cardiovascular events (MACE) driven by the progression of non-target lesions (NTLs) remains substantial and continues to increase, while current risk stratification tools remain inadequate for predicting NTL progression. This multicenter cohort study aims to develop an artificial intelligence (AI)-driven system for the dynamic prediction and precision stratification of NTL progression after PCI. Utilizing comprehensive multimodal data from 52,577 Chinese patients-including clinical profiles, multi-omics blood biomarkers, and coronary imaging-the research pursues three primary objectives: (1) to identify and validate 2-3 specific biomarkers for NTL progression risk using multi-omics approaches; (2) to construct an integrated risk assessment and early-warning system by applying machine learning to multimodal data for predicting NTL progression and MACE; and (3) to establish metabolic and imaging-based subtypes to create a precision management system that optimizes secondary prevention strategies by identifying specific high-risk populations. This study is expected to provide a novel tool for accurate identification of high-risk patients and personalized post-PCI management, ultimately aiming to improve long-term prognosis.",[29],[310,311,312,35],"Artificial Intelligence","Non-Target LesIon Progression","Percutaneous Coronary Intervention","2025-12-17",{"date":315,"type":41},"2025-12-31",{"date":317,"type":41},"2025-09-01",{"date":319,"type":22},"2026-08-31",{"name":321,"class":48},"China-Japan Friendship Hospital",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":330,"targetDuration":332,"studyType":23,"phases":4,"briefSummary":333,"conditions":334,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":4},"100610682","coronary-heart-disease-complicated-with-ischemic-mitral-regurgitation-in-china-100610682","NCT07230756","Coronary Heart Disease Complicated With Ischemic Mitral Regurgitation in China","A Prospective Cohort Study of Coronary Heart Disease Complicated With Ischemic Mitral Regurgitation in China","China-IMR","Inclusion Criteria:\n\n* Age ≥18 years, secondary mitral regurgitation discovered during outpatient visit or hospitalization;\n* Have definite coronary heart disease\n* Cardiac ultrasound: consistent with mitral regurgitation caused by myocardial ischemia or myocardial infarction:\n\n  1. Segmental wall motion abnormality or\n  2. Mitral regurgitation is consistent with Carpentier type IIIb (eccentric regurgitation)\n* Cardiac ultrasound prompts: moderate or above ischemic mitral regurgitation\n\nExclusion Criteria:\n\n* Patients within the past year or currently participating in other clinical studies;\n* Primary mitral regurgitation (such as mitral valve prolapse, perforation, chordae tendineae rupture, etc.);\n* Dilated cardiomyopathy, hypertrophic cardiomyopathy and other diseases;\n* Moderate and above aortic stenosis\u002Fregurgitation, mitral stenosis, tricuspid stenosis, etc.;\n* Patients who have undergone cardiac valve intervention\u002Fsurgery.",{"count":331,"type":22},6000,"2 Years","This project will rely on the established multi-center cooperation platform for total valve disease and based on the Carpentier classification, which is newly proposed and widely recognized by the academic community, and will specifically target the population with coronary heart disease combined with Ischemic Mitral Regurgitation（IMR） to conduct a nationwide, multi-center, single valve disease, prospective cohort. Research. From November 2025 to December 2025, 6,000 patients with coronary heart disease combined with moderate or above IMR were consecutively selected from outpatients or inpatients in 21 regional medical centers across the country, and clinical characteristics, imaging data, and serology were collected. Information, drug\u002Fsurgical intervention status and clinical outcome indicators were included in the clinical follow-up at baseline, 3 months, 6 months, 12 months and 24 months respectively. The main research objectives are to describe the disease characteristics, treatment status and clinical outcomes of coronary heart disease patients with IMR; to evaluate the current application status of GDMT strategies in IMR diagnosis and treatment practice and its impact on mid- and long-term prognosis. The secondary research objectives are to identify factors affecting prognosis, construct a risk stratification model for mid- and long-term prognosis, and discover new molecular markers.\n\nThis project will for the first time construct the world's largest clearly defined cohort of coronary heart disease combined with IMR. Its research results can provide high-quality data and decision-making basis for precise diagnosis and treatment of IMR populations. Therefore, this project has important scientific research value and clinical guidance significance.",[335,29],"Ischemic Mitral Regurgitation","2025-11-14",{"date":338,"type":41},"2025-11-17",{"date":340,"type":22},"2025-11-10",{"date":342,"type":22},"2029-12-31",{"name":250,"class":251},{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":352,"targetDuration":354,"studyType":23,"phases":4,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":49},"100532748","clinical-outcomes-of-patients-with-coronary-artery-disease-100532748","NCT06216847","Clinical Outcomes of Patients With Coronary Artery Disease","Clinical Outcomes of Patients With Coronary Artery Disease Cohort Study","COCAD","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Hospitalization due to either confirmed or suspected CHD combined with one of the following features: previous PCI or CABG; previous myocardial infarction; previous coronary angiography revealing ≥ 50% stenosis in major coronary vessels; presentation with chest pain and pre-test probability of CHD \\> 65%; laboratory tests revealing objective evidence of myocardial ischemia; coronary CT angiography (CTA) showed ≥ 30% stenosis in major coronary vessels\n* Subjects undergoing at least one coronary imaging and one functional examination. Imaging examinations include coronary CTA, intravascular ultrasound (IVUS), or optical coherence tomography (OCT). Functional examination include fraction flow reservation (FFR), CT-FFR or quantitative flow ratio (QFR).\n* Written informed consent provided.\n\nExclusion Criteria:\n\n* History of mental illness, drug or alcohol abuse, or being unable to cooperate with follow-up visits for any reason;\n* Life expectancy \\\u003C1 year\n* Pregnant or plan to be pregnant within 1 year\n* Subjects participating in any other clinical trial\n* Other conditions deemed unsuitable for inclusion by the investigator",{"count":353,"type":22},10000,"5 Years","Coronary heart disease (CHD) stands as a foremost contributor to global mortality, characterized by complex pathogenesis that renders conventional \"one-size-fits-all\" preventive strategies inefficient. Therefore, the investigators designed a prospective, multi-center cohort study among patients hospitalized due to either confirmed or suspected CHD, which aimed to establish a holographic data set for the diagnosis and treatment of CHD and explore the impact of critical therapeutic strategies in the real world on the clinical outcomes of CHD patients, providing evidence to optimize the management pathway.",[29],"2025-09-03",{"date":359,"type":41},"2025-09-10",{"date":361,"type":41},"2024-02-21",{"date":363,"type":22},"2030-10-31",{"name":365,"class":48},"Shenyang Northern Hospital",{"id":367,"slug":368,"hasResults":11,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":181,"enrollmentInfo":373,"targetDuration":4,"studyType":61,"phases":375,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":49},"100604810","community-exercise-treating-effect-on-cardiopulmonary-disease-patients-100604810","NCT07154355","Community Exercise Treating Effect on Cardiopulmonary Disease Patients","Clinical Study Protocol on the Impact of Community-Based Exercise Training on the Exercise Capacity of Patients With Reduced Cardiovascular and Pulmonary Function","Inclusion Criteria:\n\n1. Patients aged 18 to 85 with abnormal pulmonary or cardiovascular function.\n2. Individuals who have completed a medical screening form to confirm they are free from illnesses and prescription medications that could impair their ability to complete the required testing and fitness training.\n3. Participants who did not engage in structured, systematic moderate-to-intense strength or endurance training during the study period (specifically, not within the previous year).\n4. At the onset of the trial, participants were physically active but had never participated in formal exercise more than twice a week.\n\nExclusion Criteria:\n\n1. Patients with neuromuscular or skeletal disorders, or systemic diseases such as diabetes, cancer, or heart disease.\n2. Individuals using medications known to affect health or the interpretation of study results.\n3. Participants who have engaged in organized, systematic endurance or strength training of moderate to high intensity within the past year.\n4. Patients who decline to participate in the study.\n5. Other medical conditions or states that render exercise training inappropriate.",{"count":374,"type":22},200,[63],"The goal of this clinical trial is to learn if community-based exercise training can benefit patients aged 18 to 85 with diminished cardiovascular and pulmonary function. The main aim of this study is:\n\n• Establish a community or home-based fitness training program for patients with cardiopulmonary insufficiency to improve adherence, safety, and efficacy while alleviating the burden on both patients and society.\n\nResearchers will compare community-based exercise training to non-exercise training to see if community-based exercise training works to improve cardiovascular and pulmonary function.\n\nParticipants will:\n\n* Engage in community or home exercise training for 40-60 minutes, five times weekly, during a duration of eight weeks. Exercise modalities are primarily determined by the patients' individual preferences and habits, such as brisk walking, running, swimming, cycling, and hiking.\n* Adjust the exercise intensity according to their cardiopulmonary exercise test and the person's perceived exertion level.\n* Utilize fitness bracelets or watches to document statistics during workouts and submit them to the experimenter weekly, covering the five days of exercise within that week.\n* refrain from making any dietary modifications throughout the trial.",[29,28,378,379,380,381,382,383],"Cardiomyopathy","COPD","Bronchial Asthma","Respiratory Failure","Thoracic Tumors","Cardiopulmonary Diseases","2025-08-26",{"date":386,"type":41},"2025-09-04",{"date":388,"type":41},"2025-01-30",{"date":390,"type":22},"2030-12",{"name":392,"class":48},"Guangdong Provincial People's Hospital",{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":399,"sex":17,"minAge":400,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":403,"conditions":404,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":49},"100604451","village-based-management-of-chronic-cardiovascular-disease-in-qu-jiang-elderly-population-registry-the-bouquet-cohort-study-100604451","NCT07149688","Village-Based Management of Chronic Cardiovascular Disease in Qu Jiang Elderly Population Registry: The BOUQUET Cohort Study","Inclusion Criteria\n\nAge ≥60 years\n\nResident of Qujiang District\n\nDiagnosed with chronic CVD (hypertension, coronary artery disease, heart failure, atrial fibrillation, or others)\n\nAble and willing to provide informed consent\n\nExclusion Criteria\n\nSevere cognitive impairment or inability to provide consent\n\nLife expectancy \\\u003C1 year due to non-cardiovascular disease\n\nParticipation refusal",true,"60 Years",{"count":402,"type":22},30000,"This is a prospective observational cohort study conducted in Qujiang District, Zhejiang Province, China, aiming to evaluate the effectiveness of a comprehensive management program for elderly patients with chronic cardiovascular diseases (CVDs). The program integrates pharmacological treatment, lifestyle modification, health education, and long-term follow-up, with enhanced monitoring using 7-day ECG recording. The study focuses on major chronic CVDs including hypertension, coronary artery disease, atrial fibrillation, and heart failure. Approximately 30,000 participants aged ≥60 years will be enrolled and followed for up to 10 years.",[405,406,29,28],"Atrial Fibrillation (AF)","Hypertension","2025-08-24",{"date":409,"type":41},"2025-09-02",{"date":411,"type":41},"2024-03-01",{"date":413,"type":22},"2035-03-01",{"name":415,"class":48},"Beijing Anzhen Hospital",{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":424,"targetDuration":4,"studyType":61,"phases":426,"briefSummary":427,"conditions":428,"keywords":429,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":439,"locationsCount":49},"100601381","effect-of-ehealth-cardiac-rehabilitation-incorporating-mindfulness-for-patients-with-coronary-heart-disease-100601381","NCT07109752","Effect of eHealth Cardiac Rehabilitation Incorporating Mindfulness for Patients With Coronary Heart Disease","Effect of Mindfulness-based eHealth Cardiac Rehabilitation on Psychological Wellbeing and Risk Factor Management of Patients With Coronary Heart Disease: A Randomized Controlled Trial","eCR","Inclusion Criteria:\n\nPeople will be eligible for this study if they were:\n\n1. diagnosed with CHD (within the past 6 months),\n2. undergone conservative treatment, such as percutaneous coronary intervention (PCI) and\u002F or medication,\n3. currently under stable medication regimen and discharged to home.\n4. aged 18 years or older,\n5. reported scores ranging from 3 (to some degree) to 5 (very much) scores on a single-item stress symptoms scale (Elo et al., 2003),\n6. using a computer and\u002For smartphone to access the Internet at home,\n7. and, read and speak Chinese.\n\nExclusion Criteria:\n\n1. diagnosis of acute psychotic disease;\n2. presence of a life-limiting condition;\n3. prescribed contradictions to physical activity; and,\n4. presence of hearing, visual, or ambulatory disorders",{"count":425,"type":22},146,[63],"People with coronary heart disease (CHD) often feel more stressed, which can increase the risk of having another heart problem. Cardiac rehabilitation (CR) is a common treatment for those with CHD, focusing on changing lifestyles and managing the disease. However, it often does not address stress management adequately. There is also a lack of psychological therapy and involvement of mental health professionals in online CR programs. Because traditional CR programs have low participation rates, online platforms are becoming more popular for providing rehabilitation support. This is important because more than half of people with CHD report high stress levels, which can cause or worsen heart problems. To address this issue, the proposed study will test an online CR program that includes mindfulness to help manage stress for CHD patients.",[29],[430,431,432],"cardiac rehabilitation","mindfulness","eHealth","2025-07-30",{"date":435,"type":41},"2025-08-07",{"date":437,"type":41},"2024-07-20",{"date":288,"type":22},{"name":440,"class":48},"Tung Wah College",{"id":442,"slug":443,"hasResults":11,"nctId":444,"briefTitle":445,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":447,"targetDuration":449,"studyType":23,"phases":4,"briefSummary":450,"conditions":451,"keywords":452,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":460,"locationsCount":4},"100582543","assessment-of-the-diagnostic-performance-of-the-detection-system-and-establishment-of-an-intelligent-and-rapid-triage-model-100582543","NCT06864676","Assessment of the Diagnostic Performance of the Detection System and Establishment of an Intelligent and Rapid Triage Model","Inclusion Criteria:\n\n* Adults aged 18 years or above from China, regardless of gender;\n* Presence of symptoms such as chest tightness and chest pain, with the need to determine whether they are patients with acute coronary syndrome;\n* Ability to obtain informed consent.\n\nExclusion Criteria:\n\n* \\- Patients with STEMI at the time of presentation;\n* Patients with a clear diagnosis after tests such as troponin;\n* Patients who have undergone major surgery or trauma within the past four weeks;\n* Pregnant women or patients with tumors undergoing radiotherapy or chemotherapy;\n* Patients who have previously participated in this study.",{"count":448,"type":22},2000,"6 Months","The rapid triage of patients with acute chest pain remains an important issue in clinical practice. This study will establish a cohort of patients suspected of acute coronary syndrome (ACS) to construct a multi-marker dynamic combined intelligent triage model. This model will triage the risk of NSTEMI in patients with chest pain at their first visit. It will also stratify the risk of patients with chest pain using major adverse cardiovascular events (MACE) within 30 days as the endpoint.",[29],[453],"ACS","2025-03-04",{"date":456,"type":41},"2025-03-07",{"date":458,"type":22},"2025-03",{"date":192,"type":22},{"name":250,"class":251},{"id":462,"slug":463,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":11,"sex":17,"minAge":468,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":471,"conditions":472,"keywords":475,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":4},"100577306","reliability-of-multiple-repetition-maximum-tests-in-patients-with-cardiovascular-disease-or-risk-factors-100577306","NCT06796582","Reliability of Multiple-Repetition-Maximum Tests in Patients with Cardiovascular Disease or Risk Factors","Agreement of the Estimated 1-Repetition-Maximum Between Two Multiple-Repetition-Maximum Tests with Different Weight in Patients with Cardiovascular Disease or Risk Factors","Inclusion Criteria:\n\n* Age ≥ 50 years\n* At least one of the following cardiovascular diseases \u002F risk factors:\n* Heart failure\n* Coronary heart disease\n* Atrial fibrillation\n* Arterial hypertension\n* Type 2 diabetes mellitus\n* Clinically stable for ≥ 4 weeks\n* Medical clearance to perform resistance training \u002F strength testing\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Acute infection\n* Chronic joint inflammation\n* Knee, hip, ankle, wrist, elbow or shoulder pain\n* Known osteoporosis (T-value ≤ -2.5)\n* Uncontrolled hypertension (≥160 mmHG systolic \u002F ≥100 mmHG diastolic)\n* Known cerebral or thoracic aneurysm","50 Years",{"count":470,"type":22},50,"Exercise training is a cornerstone in the prevention and rehabilitation of cardiovascular disease. While research has primarily focused on endurance training, resistance training becomes more and more important. The gold standard to prescribe resistance training intensity or monitor longitudinal changes is the 1-Repetition-Maximum (1-RM) test. However, particularly for unexperienced individuals, this test may not be recommendable due to the high load and an increased risk of injuries. Alternatively, there are several published formulas to estimate the 1-RM based on a multiple-repetition-maximum (or repetition-to-failure) test. However, these formulas have been primarily tested in healthy individuals. Moreover, the reliability of the 1-RM estimation based on two tests with different submaximal weight is unknown. Therefore, the present study evaluates the agreement of the 1-RM estimation (based on different formulas) between two Multiple-RM tests with different weight in 50 patients with cardiovascular disease (heart failure, coronary heart disease, atrial fibrillation) or cardiovascular risk factors (type 2 diabetes, arterial hypertension).",[28,29,405,473,474],"Diabetes Mellitus","Arterial Hypertension",[476,477,478,479],"resistance training","cardiovascular disease","cardiovascular risk factors","muscle strength","2025-01-27",{"date":482,"type":41},"2025-01-29",{"date":484,"type":22},"2025-02",{"date":486,"type":22},"2025-06",{"name":488,"class":48},"Technical University of Munich",{"id":490,"slug":491,"hasResults":11,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":497,"enrollmentInfo":498,"targetDuration":4,"studyType":61,"phases":500,"briefSummary":501,"conditions":502,"keywords":506,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":514,"leadSponsor":515,"locationsCount":49},"100572079","protective-effect-of-eecp-against-negative-inflammatory-response-and-organ-dysfunction-after-cardiovascular-surgery-100572079","NCT06728605","Protective Effect of EECP Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery","Protective Effect of Enhanced External Counterpulsation Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery","PANDA","Inclusion Criteria:\n\n* Age \\> 18 years;\n* Patients with Stable angina pectoris, unstable angina pectoris, acute myocardial infarction, congestive heart failure, cardiogenic shock;\n* Patients chronic heart failure;\n* Patients are ready to received cardiovascular surgery during this hospital admission.\n* Patients agree to participate in the study and sign an informed consent form.\n\nExclusion Criteria:\n\n1\\. Moderate to severe aortic insufficiency; 2. Dissection aneurysm; 3. Significant pulmonary hypertension; 4, A variety of bleeding diseases or bleeding tendencies, or use anticoagulants, INR\\>2.0; 5, active phlebitis, venous thrombosis; 6. There is an infection in the counterpulsating limb; 7. Uncontrolled hyperhypertension (\\>170\u002F110mmHg); 8. Uncontrolled arrhythmias: frequent premature beats, rapid atrial fibrillation, etc.\n\n9\\. Pregnancy.","80 Years",{"count":499,"type":22},400,[63],"Enhanced external counterpulsation (EECP) is a noninvasive, non-pharmacologic intervention proven to increase nitric oxide bioavailability in patients with coronary artery disease. Although EECP showed short-term effects in improving coronary flow in patients with coronary slow flow, whether such improvement is durable remains uncertain, and the relationships between such improvement and changes in multiple organ functions as well as inflammatory markers have not been elucidated. The purpose of this study will be to evaluate the potential clinical benefits of EECP on organ function and proinflammatory cytokine concentrations during post-acute sequela of cardiovascular surgery.",[29,503,504,505],"Cardio-pulmonary Bypass","Congestive Heart Failure Chronic","Cardiogenic Shock Acute",[507,508,509],"cardiac surgery","cardiopulmonary bypass","cardiogenic shock","2024-12-10",{"date":512,"type":41},"2024-12-11",{"date":315,"type":22},{"date":315,"type":22},{"name":516,"class":48},"Nanjing Medical University",{"id":518,"slug":519,"hasResults":11,"nctId":520,"briefTitle":521,"officialTitle":521,"acronym":522,"eligibilityCriteria":523,"healthyVolunteers":399,"sex":17,"minAge":524,"maxAge":283,"enrollmentInfo":525,"targetDuration":4,"studyType":61,"phases":527,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":4},"100569517","using-retinal-photograph-based-ai-to-predict-incident-coronary-heart-disease-100569517","NCT06695273","Using Retinal Photograph Based AI to Predict Incident Coronary Heart Disease","DeepCHD Plus","Inclusion criteria:\n\n* Individuals without uncontrolled vascular risk factors\n* Age range: 40-75 years old\n* Can accept and cooperate with the examination and potential follow-up work after being selected for clinical trials\n\nExclusion criteria:\n\n* Severe lung disease and cancer or surgery patients\n* Statin user or pre-existing cardiovascular disease\n* Individuals with severe liver and kidney dysfunction and electrolyte imbalance","40 Years",{"count":526,"type":22},1570,[63],"To determine whether an integrated retinal AI decision support can improve predictive accuracy of coronary heart disease (CHD), the investigators are conducting a randomized controlled study of AI guided prediction of CHD compared to clinical prediction by physicians (e.g., usingPCEs), both using clinical intuition as baseline.",[29],"2024-11-16",{"date":532,"type":41},"2024-11-19",{"date":534,"type":22},"2025-01",{"date":536,"type":22},"2025-05",{"name":538,"class":48},"Tsinghua University",{"id":540,"slug":541,"hasResults":11,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":399,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":548,"conditions":549,"keywords":552,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":49},"100561573","a-foundational-model-for-cardiovascular-disease-diagnosis-and-prediction-100561573","NCT06591923","a Foundational Model for Cardiovascular Disease Diagnosis and Prediction","Development and Clinical Application of a Foundational Model for Cardiovascular Disease Diagnosis and Prediction Based on Multimodal Medical Big Data","Inclusion Criteria:\n\nAge ≥ 18 years: Patients who are 18 years of age or older. Time period: Patients who were treated or diagnosed between January 1, 2009, and December 31, 2023.\n\nComplete medical records: Patients with comprehensive medical records, including ECG, echocardiography, MRI, CTA, nuclear imaging (SPECT\u002FPET), and biochemical test results.\n\nCardiovascular diseases: Patients with diagnosed cardiovascular conditions, such as coronary artery disease (CAD), heart failure, arrhythmias, and valvular heart disease (VHD), as well as healthy individuals for comparison.\n\nWillingness to participate: Patients who are able to provide informed consent or their legal representatives.\n\nExclusion Criteria:\n\nParticipation in other clinical trials: Patients who are currently participating in other clinical trials that may affect the study outcomes.\n\nIncomplete medical records: Patients whose medical records lack essential data, such as ECG, echocardiography, MRI, CTA, nuclear imaging (SPECT\u002FPET), or biochemical test results.\n\nData quality issues: Patients with records that have significant errors, inconsistencies, or incomplete data that cannot be reasonably corrected.\n\nEthical or legal concerns: Patients whose data cannot be used due to a lack of necessary consent or legal\u002Fethical restrictions.",{"count":547,"type":22},1000000,"The goal of this observational study is to develop and evaluate the efficacy of a foundational model that integrates multimodal medical data to improve the diagnosis and prediction of cardiovascular diseases in patients aged 18 and older, including those with various heart conditions such as coronary artery disease, heart failure, and arrhythmias. The main questions it aims to answer are:\n\nCan a multimodal data-based diagnostic model match or exceed the accuracy of traditional gold-standard methods like coronary angiography, MRI, and echocardiography? Does integrating different types of data (ECG, imaging, biochemical tests) improve diagnostic accuracy and prediction of cardiovascular disease outcomes? Researchers will compare the foundational model with traditional diagnostic methods to see if the model offers better sensitivity, specificity, and prediction accuracy across different heart disease types.\n\nParticipants will:\n\nProvide data from past medical records, including ECG, echocardiography, cardiac MRI, and biochemical tests.\n\nUndergo further data collection if necessary, in line with standard clinical procedures for cardiovascular disease management.",[29,28,550,551],"Arrhythmias","Valvular Heart Disease",[553,241],"foundation model","2024-09-08",{"date":556,"type":41},"2024-09-19",{"date":558,"type":22},"2024-10",{"date":560,"type":22},"2025-04",{"name":274,"class":48}]